Phaseline

Targets › SLC31A1

SLC31A1 (High affinity copper uptake protein 1): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 2; Oncology, Metabolic and endocrine; next expected readout Mar 2030.

[High affinity copper uptake protein 1]: Uniporter that mediates the transport of copper(1+) from the extracellular space to the cytoplasm, across the plasma membrane and delivers directly copper(1+) to specific chaperone such as ATOX1, via a copper(1+)- mediated transient interaction between the C-terminal domain and a copper(1+) chaperone, thus controlling intracellular copper(1+) levels. May function in…. (UniProt, O15431)

Open in Phaseline: the race on SLC31A1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Osaka UniversityOxaliplatin
Platinum-based DNA crosslinking agent
SLC31A1Phase 2Rectal CancerMar 2030
Universitas IndonesiaZinc, Chromium, Vitamin C, and Copper Supplementation
Combination mineral and vitamin supplement: zinc enhances insulin signaling and glucose me
SLC30A1, CREBBP, SLC31A1Phase 2PreDiabetes–

Conditions

Rectal Cancer (1) PreDiabetes (1)

Modalities

–

Companies

Osaka University (1) Universitas Indonesia (1)

Related targets

SLC30A1 (1) CREBBP (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.